ArticleBMC endocrine disorders2026
Multi-trajectory modeling of metabolic syndrome indicators and cardiovascular disease risk: a study based on health examination big data.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical utility of metabolic syndrome (MetS) in predicting cardiovascular disease (CVD) and diabetes has been questioned due to its binary definition, which results in substantial loss of information from metabolic indicators. This study aims to longitudinally evaluate MetS measurement indicators, identify their multi-trajectory patterns over time, and assess the associated CVD risk.
methodsGroup-based multi-trajectory modeling (GBMTM) was applied to metabolic syndrome indicators to identify multi-trajectory patterns and describe baseline characteristics of subgroups. Subsequently, with CVD as the outcome, trajectory groups were incorporated into interval-censored Cox proportional hazards models to estimate the associated CVD risks across different trajectory patterns.
resultsThis study identified five distinct metabolic patterns through trajectory typing. The “progressive hyperglycemia trajectory” (characterized by high and continuously increasing fasting plasma glucose [FPG] levels) and the “persistent dyslipidemia trajectory” (characterized by persistently high triglycerides [TG], low high-density lipoprotein cholesterol [HDL-C] with continuous decrease) demonstrated higher CVD incidence density. After adjusting for age and sex, their hazard ratios (HR) were 1.469 (95% CI: 1.319–1.635) and 1.355 (95% CI: 1.189–1.544), respectively.
conclusionsThis study identified five distinct longitudinal trajectories of MetS indicators and demonstrated their significant associations with CVD risk. The progressive hyperglycemia trajectory and the persistent dyslipidemia trajectory were associated with higher CVD risk, underscoring the importance of longitudinal monitoring of FPG, TG, and HDL-C for CVD prevention in elderly populations. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.